Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ESPR Esperion Therapeutics
5.900-0.020-0.34%
Close
02/03 16:00 ET
6.040+0.140+2.37%
Post Mkt Price 02/03 18:53 ET
High
6.269
Open
6.140
Turnover
12.86M
Low
5.840
Pre Close
5.920
Volume
2.17M
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Esperion Therapeutics Raised to Equal-Weight From Underweight by Morgan Stanley
Esperion Therapeutics Price Target Announced at $9.00/Share by Morgan Stanley
Morgan Stanley Upgrades Esperion Therapeutics to Equal-Weight, Announces $9 Price Target
Morgan Stanley analyst Jeffrey Hung upgrades Esperion Therapeutics (NASDAQ:ESPR) from Underweight to Equal-Weight and announces $9 price target.
Analysts Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Price Target at $11.20
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating) has received a consensus rating of "Hold" from the six analysts that are covering the stock, MarketBeat.com reports. Two equities research anal
The Past Five Years for Esperion Therapeutics (NASDAQ:ESPR) Investors Has Not Been Profitable
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of "Hold" by Brokerages
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating) have earned an average rating of "Hold" from the six ratings firms that are presently covering the company, MarketBeat.com reports. T
Esperion Therapeutics (NASDAQ:ESPR) Shares Up 3.3%
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating) shot up 3.3% during trading on Tuesday . The stock traded as high as $6.91 and last traded at $6.91. 115,696 shares traded hands durin
Insider Selling: Esperion Therapeutics, Inc. (NASDAQ:ESPR) General Counsel Sells $44,429.00 in Stock
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating) General Counsel Benjamin Looker sold 6,347 shares of Esperion Therapeutics stock in a transaction dated Wednesday, January 18th. The stock was s
Esperion Therapeutics (NASDAQ:ESPR) Trading Down 5.6%
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating)'s stock price fell 5.6% during trading on Thursday . The company traded as low as $6.41 and last traded at $6.89. 113,555 shares were traded du
MELI, QRVO and ESPR Are Among After Hour Movers
Company Overview
More
Esperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
CEO： Mr. Sheldon L. Koenig
Market： NASDAQ
Listing Date： 06/26/2013
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet